
Brian C. Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life.

Brian C. Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life.

Menin inhibitors such as ziftomenib and revumenib target NPM1 and KMT2A AML, pushing precision therapy earlier with manageable toxicity.

Obesity rewires DCIS-to-IDC invasion via metabolic stress, inflammatory signaling and SULF2, revealing an immunosuppressive niche

In an interview, Joseph Mikhael, MD, MEd, discusses the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.

Learn how NPM1 MRD qPCR predicts relapse, shapes transplant decisions, and emerging trials test MRD negativity as a treatment target in AML.

Triplet therapy with ziftomenib, venetoclax, and azacitidine boosts responses in venetoclax‑naive NPM1‑mutated AML; phase 3 trials test frontline benefit.

Joseph Mikhael, MD, MEd, explains the function and potential benefits of the on-body injector now approved for use with isatuximab in multiple myeloma.

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening.

Explore how allostatic load, using routine labs and vitals, may strengthen early-onset cancer risk prediction and guide earlier prevention in community oncology.

Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device.

MD Anderson trials test psilocybin therapy for head and neck cancer patients and survivors, aiming to curb suicide risk and ease treatment trauma.

KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable toxicity and longer responses.

KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses and guide future menin-based regimens.

Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.

New research shows T-cell receptor sequencing can reveal immune signatures of precancer and cancer in Lynch syndrome carriers, aiding early detection.

Doris K. Hansen, MD, discusses what she hopes long-term real-world data on CAR T-cell therapy will show in order to better inform treatment of multiple myeloma.

A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the landmark ALEX trial.

Heather J. Landau, MD, discusses the most exciting outcomes observed in a trial of BCMA-targeted NXC-201 for light chain amyloidosis.

Doris K. Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.

Lung cancer increasingly hits never-smoking women; learn how biomarker testing, earlier screening, and stronger self-advocacy speed diagnosis and unlock better treatments.

Two new oncologists share raw truths on fellowship loneliness, fear of autonomy, and building networks that make the leap to faculty survivable.

Oral golcadomide with rituximab delivers high responses and manageable safety, enabling outpatient care for relapsed follicular lymphoma.

Golcadomide plus rituximab shows deep, durable responses in relapsed follicular lymphoma, with manageable neutropenia and limited added toxicity.

In an interview, Melody Chang, MBA, RPh, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

Adam Cuker, MD, MS, discusses how the goals of treatment for immune thrombocytopenia have developed beyond managing platelet count.

Peter Voorhees, MD, discusses the cost-benefit question of adding pomalidomide to daratumumab and talquetamab in early relapsed multiple myeloma.

In an interview, Peter Voorhees, MD, discusses why talquetamab is typically sequenced after BCMA-targeting agents and the unique situations where it might be used first.

Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.

Genome sequencing speeds tumor mutation discovery, boosting targeted cancer therapies and cell/gene treatments while raising urgent questions about data ownership, reporting uncertainty, and ethics.